ECOG-ACRIN opens a new NCI-MATCH treatment arm for dMMR and LAG-3-positive cancers as it continues to locate patients with BRAF mutations
The groundbreaking NCI-MATCH trial continues to offer treatment opportunities for adult patients with relapsed, refractory cancers. A new treatment arm ...